Collaborative Drug Therapy Management (CDTM)

Information for Pharmacists

The Board of Medical Examiners and the Board of Pharmacy have jointly promulgated rules that permit physicians and pharmacists to formally collaborate in the management of drug therapy for certain conditions in their patients. Before you begin the formal application process, we strongly encourage you to review the rules to ensure your understanding of the limitations and standards of practice required in such professional activities. The rules from both boards have been published on their respective websites: www.lsbme.la.gov and www.labp.com.

The approval to collaborate in drug therapy management requires two applications.

- Pharmacists shall apply to the Board of Pharmacy, and physicians shall apply to the Board of Medical Examiners, for a CDTM Registration. The issuance of a registration by the Board is conditioned upon the applicant’s demonstration they have met the eligibility criteria specified in the rules. When issued, the Board of Pharmacy’s CDTM Registration will arrive in the form of a letter containing a CDTM Registry Number. While the registration, like your license, is permanent, you shall renew it annually at the same time you renew your pharmacist license. There is no fee for the issuance or renewal of a CDTM Registration.

- A pharmacist and physician, when both are in possession of a CDTM Registration from their respective boards, who wish to engage in CDTM activities shall file a Notice of Intent to Collaborate. This form shall be signed by the pharmacist and the physician and then submitted to the CDTM Advisory Council at the Board of Medical Examiners. As indicated in the instructions on the notice, the collaborative practice agreement shall be appended to that form.

The CDTM Advisory Council is a formal subunit of the Board of Medical Examiners, and it is composed of four physicians and three pharmacists. Among other duties, this advisory council shall review all Notices of Intent to Collaborate to ensure the agreements are in compliance with all standards specified in the rules. When appropriate, they shall make a recommendation to the Board of Medical Examiners for approval of the contemplated CDTM activities. When appropriate, the Board of Medical Examiners shall approve the Notice of Intent to Collaborate. On receipt of that approval, the pharmacists and physicians may engage in the CDTM activities specified in the collaborative practice agreement approved by the Board of Medical Examiners.

Although the rules do place limits on the types of conditions for which drug therapy may be collaboratively managed, there are no limits on the number of collaborative practice agreements in which pharmacists or physicians may participate. Thus, one pharmacist may choose to collaborate with more than one physician; each such collaborative effort shall require a separate collaborative practice agreement, as well as a separate Notice of Intent to Collaborate.